| RESEARCH ARTICLE |
|
| Year : 2003 | Volume
: 19
| Issue : 2 | Page : 113-116 |
|
|
Doxazocin in management of benign prostatic hyperplasia
NK Mohanty, RP Arora, AK Jha, S Singh Pal
Department of Urology, Safdarjang Hospital, New Delhi, India
Correspondence Address:
N K Mohanty
D-11/87, West Kidwai Nagar, New Delhi - 110 023
India
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
A total 220 patients with benign prostatic hyperplasia (BPH) but not having absolute indication for surgery were enrolled for 8 weeks single label study, using doxazocin (Doxacard) 4 mg daily for their features of prostatism, with a six month follow up. The study revealed an improvement of 90% in their symptoms at the end of the study with an increase of maximum flow rate (MFR) by 5-5.5 ml/sec and average flow rate (AFR) 2.5-3 ml/sec. Adverse effects were minimum and patient compliance was very good with good drug tolerability. Our study strongly supports the use of doxazocin as an alternative in the management of uncomplicated BPH with hypertension. |
|
|
|
| [FULL TEXT] [PDF Not available]* |
|
 |
|
